Immune dysregulation in cancer patients developing immune-related adverse events von Khan, Shaheen, Khan, Saad A., Luo, Xin, Fattah, Farjana J., Saltarski, Jessica, Gloria-McCutchen, Yvonne, Lu, Rong, Xie, Yang, Li, Quan, Wakeland, Edward, Gerber, David E.

Volltext

The transcription factor TFII-I promotes DNA translesion synthesis and genomic stability von Fattah, Farjana J, Hara, Kodai, Fattah, Kazi R, Yang, Chenyi, Wu, Nan, Warrington, Ross, Chen, David J, Zhou, Pengbo, Boothman, David A, Yu, Hongtao

Volltext

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors von von Itzstein, Mitchell S., Gonugunta, Amrit S., Wang, Yiqing, Sheffield, Thomas, Lu, Rong, Ali, Sadia, Fattah, Farjana J., Xie, Donglu, Cai, Jennifer, Xie, Yang, Gerber, David E.

Volltext

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer von Gong, Ke, Guo, Gao, Gerber, David E, Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D, Hatanpaa, Kimmo J, Kernstine, Kemp, Cai, Ling, Xie, Yang, Zhu, Hong, Fattah, Farjana J, Zhang, Shanrong, Takahashi, Masaya, Mukherjee, Bipasha, Burma, Sandeep, Dowell, Jonathan, Dao, Kathryn, Papadimitrakopoulou, Vassiliki A, Olivas, Victor, Bivona, Trever G, Zhao, Dawen, Habib, Amyn A

Volltext

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors von Huang, Xiumei, Motea, Edward A., Moore, Zachary R., Yao, Jun, Dong, Ying, Chakrabarti, Gaurab, Kilgore, Jessica A., Silvers, Molly A., Patidar, Praveen L., Cholka, Agnieszka, Fattah, Farjana, Cha, Yoonjeong, Anderson, Glenda G., Kusko, Rebecca, Peyton, Michael, Yan, Jingsheng, Xie, Xian-Jin, Sarode, Venetia, Williams, Noelle S., Minna, John D., Beg, Muhammad, Gerber, David E., Bey, Erik A., Boothman, David A.

Volltext

Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells von Fattah, Farjana, Lee, Eu Han, Weisensel, Natalie, Wang, Yongbao, Lichter, Natalie, Hendrickson, Eric A

Volltext

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer von Bhalla, Sheena, Fattah, Farjana J., Ahn, Chul, Williams, Jessica, Macchiaroli, Alyssa, Padro, Jonathan, Pogue, Meredith, Dowell, Jonathan E., Putnam, William C., McCracken, Nigel, Micklem, David, Brekken, Rolf A., Gerber, David E.

Volltext

DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors von Chung, Jin-Sung, Ramani, Vijay, Kobayashi, Masato, Fattah, Farjana, Popat, Vinita, Zhang, Song, Cruz, Jr, Ponciano D, Gerber, David E, Ariizumi, Kiyoshi

Volltext

XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition von Patidar, Praveen L., Viera, Talysa, Morales, Julio C., Singh, Naveen, Motea, Edward A., Khandelwal, Megha, Fattah, Farjana J.

Volltext

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors von von Itzstein, Mitchell S., Gonugunta, Amrit S., Wang, Yiqing, Sheffield, Thomas, Lu, Rong, Ali, Sadia, Fattah, Farjana J., Xie, Donglu, Cai, Jennifer, Xie, Yang, Gerber, David E.

Volltext

Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer von Gerber, David E, Putnam, William C, Fattah, Farjana J, Kernstine, Kemp H, Brekken, Rolf A, Pedrosa, Ivan, Skelton, Rachael, Saltarski, Jessica M, Lenkinski, Robert E, Leff, Richard D, Ahn, Chul, Padmanabhan, Chyndhri, Chembukar, Vaidehi, Kasiri, Sahba, Kallem, Raja Reddy, Subramaniyan, Indhumathy, Yuan, Qing, Do, Quyen N, Xi, Yin, Reznik, Scott I, Pelosof, Lorraine, Faubert, Brandon, DeBerardinis, Ralph J, Kim, James

Volltext

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon von Khan, Shaheen, von Itzstein, Mitchell S., Lu, Rong, Bermas, Bonnie L., Karp, David R., Khan, Saad A., Fattah, Farjana J., Park, Jason Y., Saltarski, Jessica M., Gloria‐McCutchen, Yvonne, Xie, Yang, Li, Quan‐Zhen, Wakeland, Edward K., Gerber, David E.

Volltext

Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells von Fattah, Farjana J, Lichter, Natalie F, Fattah, Kazi R, Oh, Sehyun, Hendrickson, Eric A

Volltext

Statin Intolerance, Anti‐HMGCR Antibodies, and Immune Checkpoint Inhibitor‐Associated Myositis: A “Two‐Hit” Autoimmune Toxicity or Clinical Predisposition? von von Itzstein, Mitchell S., Khan, Shaheen, Popat, Vinita, Lu, Rong, Khan, Saad A., Fattah, Farjana J., Park, Jason Y., Bermas, Bonnie L., Karp, David R., Ahmed, Murtaza, Saltarski, Jessica M., Gloria‐McCutchen, Yvonne, Xie, Yang, Li, Quan‐Zhen, Wakeland, Edward K., Gerber, David E.

Volltext

Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair von Morales, Julio C., Richard, Patricia, Rommel, Amy, Fattah, Farjana J., Motea, Edward A., Patidar, Praveen L., Xiao, Ling, Leskov, Konstantin, Wu, Shwu-Yuan, Hittelman, Walter N., Chiang, Cheng-Ming, Manley, James L., Boothman, David A.

Volltext

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities von Mu-Mosley, Hong, von Itzstein, Mitchell S., Fattah, Farjana, Liu, Jialiang, Zhu, Chengsong, Xie, Yang, Wakeland, Edward K., Park, Jason Y., Kahl, Brad S., Diefenbach, Catherine S., Gerber, David E.

Volltext

The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair von Patidar, Praveen L, Motea, Edward A, Fattah, Farjana J, Zhou, Yunyun, Morales, Julio C, Xie, Yang, Garner, Harold R, Boothman, David A

Volltext

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer von Gerber, David E, Boothman, David A, Fattah, Farjana J, Dong, Ying, Zhu, Hong, Skelton, Rachel A, Priddy, Laurin L, Vo, Peggy, Dowell, Jonathan E, Sarode, Venetia, Leff, Richard, Meek, Claudia, Xie, Yang, Schiller, Joan H

Volltext

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice von von Itzstein, Mitchell S, Yang, Yuqiu, Wang, Yiqing, Hsiehchen, David, Sheffield, Thomas Y, Fattah, Farjana, Popat, Vinita, Ahmed, Murtaza, Homsi, Jade, Dowell, Jonathan E, Rashdan, Sawsan, Lohrey, Jay, Hammers, Hans J, Hughes, Randall S, Wang, Tao, Xie, Yang, Gerber, David E

Volltext

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors von Ahmed, Murtaza, von Itzstein, Mitchell S, Sheffield, Thomas, Khan, Shaheen, Fattah, Farjana, Park, Jason Y, Popat, Vinita, Saltarski, Jessica M, Gloria-McCutchen, Yvonne, Hsiehchen, David, Ostmeyer, Jared, Khan, Saad A, Sultana, Nazima, Xie, Yang, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E

Volltext